A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (J2A-MC-GZGP)
- Conditions
- Obesity Overweight Overweight or Obesity
- Registration Number
- jRCT2031230136
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 3000
Have a BMI
_30.0 kilogram/square meter (kg/m2), _27.0 kg/m2 and presence of at least 1 of the following weight-related comorbidities (treated or untreated) at screening: Hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure). Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
Have Type 1 diabetes, Type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma Have a self-reported change in body weight >5 kg (11 pounds) within 90 days prior to screening. Have family (first-degree relative) or personal history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia (MEN)2 syndrome. Have had a history of chronic or acute pancreatitis.
Study & Design
- Study Type
- Interventional
- Study Design
- parallel assignment
- Primary Outcome Measures
Name Time Method - Mean Percent Change from Baseline in Body Weight [ Time Frame: Baseline to Week 72 ]
- Secondary Outcome Measures
Name Time Method